What Is TB-500? Uses, Risks, and FDA Status
What Is TB-500?
TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring 43-amino-acid peptide found in nearly all human and animal cells. Thymosin Beta-4 plays a central role in cell migration, wound healing, and tissue repair. TB-500 is the active fragment most commonly used in research and clinical contexts, and it has been studied extensively in animal models for its regenerative properties.
How Does TB-500 Work?
TB-500 works primarily by regulating actin, a protein that forms the structural framework of cells. By upregulating actin, TB-500 promotes cell migration — the process by which cells move to injury sites to begin repair. It also promotes angiogenesis (new blood vessel formation), reduces inflammation, and appears to downregulate inflammatory cytokines. Research suggests it can differentiate stem cells and promote the formation of new muscle, blood vessel, and skin cells (Goldstein et al., Expert Opin Biol Ther, 2012). These mechanisms collectively accelerate the body's natural healing processes.
What Is TB-500 Used For?
Based on published preclinical and veterinary research, TB-500 has been investigated for:
- Muscle injury recovery — Accelerated healing of muscle strains and tears in animal models
- Tendon and ligament repair — Improved healing outcomes in connective tissue injuries
- Cardiac repair — Research in mouse models suggests improved cardiac function after heart attack (Bock-Marquette et al., Nature, 2004)
- Wound healing — Accelerated closure of dermal wounds in animal studies
- Reduced inflammation — Anti-inflammatory effects observed across multiple tissue types
- Hair regrowth — Preliminary evidence of hair follicle stimulation in animal models
What Are the Risks?
- Limited human clinical data. Most TB-500 research has been conducted in animals or in veterinary (equine) settings. Human clinical trials are limited.
- Unknown long-term effects. No long-term human safety studies have been published.
- Theoretical cancer concern. Because TB-500 promotes cell migration and angiogenesis, there is a theoretical concern about its use in individuals with active or undiagnosed cancers. No direct evidence links TB-500 to cancer promotion, but the mechanism warrants caution.
- Injection site reactions. Localized redness, swelling, or irritation at the injection site.
- Quality variability. Products from unregulated sources may have inconsistent purity and potency.
FDA Status
TB-500 was removed from the FDA's Category 2 list in April 2026 and is scheduled for PCAC review on July 23, 2026 for potential addition to the 503A bulks list. It is currently in a regulatory gray zone — no longer restricted, but not yet formally authorized for compounding. It is not FDA-approved as a drug. If the PCAC votes favorably, licensed compounding pharmacies would be able to prepare it with a physician prescription.
Key Takeaway
TB-500 is a regenerative peptide with strong preclinical evidence for tissue repair and wound healing, currently awaiting a key FDA advisory committee decision that will determine its legal compounding status.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.